莉芙敏治疗妇科肿瘤患者绝经相关症状临床观察

Remifemin Treatment of Gynecological Tumor Patients' Menopause Related Symptoms

目的:观察莉芙敏(Remifemin)治疗妇科肿瘤患者经手术及放化疗出现绝经症状的临床疗效。方法:选取辽宁省肿瘤医院于2010年6月—2011年7月就诊的患者共48例。通过行问卷调查Kupermann(KMI)评分,患者符合KMI≥15,或潮热汗出单项评分>6,分为莉芙敏组(18例)、空白对照组(30例),采用秩和检验、重复测量方差分析及卡方检验。观察研究两组于治疗前和治疗后4周、8周、12周的Kupermann评分及症状表现,评价药物反应率及不良反应发生率。结果:莉芙敏组和空白对照组治疗前与治疗后4周、8周、12周KIM总分比较,两组间KMI总分比较F=16.674,P=0.000<0.05,组间差异有统计学意义,两组间效果不同。莉芙敏组潮热汗出、感觉异常、失眠、情绪激动、抑郁疑心、眩晕、乏力、骨关节痛、心悸、性生活困难各单项评分均低于治疗前(P<0.05),对照组(空白)仅心悸单项评分低于治疗前(P<0.05),其余各单项P>0.05。莉芙敏组与对照组不良反应发生情况比较,P>0.05。结论:莉芙敏能够有效治疗妇科肿瘤患者经手术及放化疗治疗后出现的绝经相关症状,有较好的安全性。

Objective ： To observe the clinical curative effect of remifemin treatment of gynecological tumors patients＇ menopause symptoms caused by surgery or radiation and chemotherapy. Methods： We selected 48 cases from June 2010 to July 2011. Through the questionnaire survey Kupermann （ KMI ） score, accord with KMI ≥ 15, or hot single score 〉 6 patients, they were divided into remifemin group 18 cases and the control group （ blank ） 30 cases. The test of repetitive measure anova, rank and inspection and a chi-square test were carried out. Before treatment and after treatment for 4 weeks, 8 weeks, 12 weeks, we observed the symptoms, Kupermann score, drug reaction rate and the evaluation of adverse reaction rate. Results： In remifemin group before and after treatment 4 weeks,8 weeks, 12 weeks, KIM total score, hot flashes, abnormal sweated insomnia, emotion, depression suspicion, dizziness, lack of power, joint pain, heart palpitations, sexual life difficult scores were less than those before treatment （ P〈0.05 ） and the control group only had palpitations single score below before treatment （P〈0.05）. Remifemin group and control group＇s adverse reaction rate was not significant （ P〉0.05 ）. Conclusion ： Remifemin can effectively treat gynecological tumors patients＇ menopause symptoms caused by surgery or radiation and chemotherapy with a good security.